Acadia Pharmaceuticals Inc.
Clinical trials sponsored by Acadia Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company developing treatments for central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough depression? drug trial targets Non-Responders Results expected Aug 2027 (estimated)
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control Stopped earlyThis study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger (hyperphagia). About 160 participants who completed a previous study will receive the spray three times daily. The goal is to see …
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Autism irritability drug trial ends early: what happened?
Symptom relief Stopped earlyThis study looked at the long-term safety of pimavanserin for treating irritability in children and teens (ages 5-17) with autism. It was an extension of an earlier 6-week study, lasting 52 weeks. The trial was terminated early, and results are not yet fully available.
Phase 2/3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC